Related Experiment Video
Updated: Jun 6, 2025
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
Published on: September 5, 2017
Health and Economic Impacts of Introducing Vaccae and Enhanced Drug-Resistant Tuberculosis Management Strategies in
Pei-Yao Zhai1, Xiao Zang2, Ting Jiang1
1Department of Infectious Diseases, Affiliated Hospital of Nantong University, Medical School of Nantong University; Nantong, JS, China.
Background:
China faces high burden of multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB). We aimed to evaluate the impacts of Vaccae vaccination and enhanced drug-resistant TB (DR-TB) management strategies.
Methods:
Using a compartmental model calibrated with national TB data, we evaluated 9 interventions: enhanced DR-TB management (S1); Vaccae vaccination for those with latent TB infection, targeting specific age groups (S2: adolescents, S3: adolescents and young adults, S4: working-age adults, S5: elderly); and combined strategies S6-S9. Vaccae's efficacy was 0.547 for the first 5 years, then waning annually. Costs were US$28/dose for Vaccae, US$87/test for Xpert MTB/RIF, and US$13 818/course for BPaLM.
Results:
Strategy S1 is projected to reduce MDR/RR-TB incidence and mortality by 21% (95% UI, 8%-46%) and 54% (38%-67%), respectively, by 2050. Strategy S9 (S5+S1) is more effective, reducing the incidence by 44% (35%-61%) and mortality by 68% (52%-78%), with an ICER of US$7222 (4460-10 779) per DALY averted compared with S1. Additionally, S9 could prevent 24.2 (13.5-32.9) million patient-months of second-line treatment from 2025 to 2050.
Conclusions:
Prioritizing Vaccae vaccination for the elderly and enhancing DR-TB management offer a promising and cost-effective opportunity for China. The findings may have policy implications for other low- and middle-income countries with high MDR/RR-TB burden.
More Related Videos
06:32Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
Related Concept Videos
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:29Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
01:26Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
01:51Vaccinations
01:29Microorganisms in Medicine and Therapeutics
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...